Trial Profile
Effect of Ranibizumab on Malignant Conjunctival Neoplasia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jul 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Eye neoplasms
- Focus Adverse reactions
- 02 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Dec 2008 Planned number of patients changed from 20 to 10 as reported by ClinicalTrials.gov.
- 30 Dec 2008 Planned end date changed from 1 Oct 2008 to 1 Oct 2009 as reported by ClinicalTrials.gov.